Besifovir (BioDeep_00000176610)
human metabolite blood metabolite
代谢物信息卡片
化学式: C10H14N5O4P (299.07833740000007)
中文名称: P-[[[1-[(2-氨基-9H-嘌呤-9-基)甲基]环丙基]氧基]甲基]-磷酸
谱图信息:
最多检出来源 Homo sapiens(blood) 75%
分子结构信息
SMILES: C1CC1(CN2C=NC3=CN=C(N=C32)N)OCP(=O)(O)O
InChI: InChI=1S/C10H14N5O4P/c11-9-12-3-7-8(14-9)15(5-13-7)4-10(1-2-10)19-6-20(16,17)18/h3,5H,1-2,4,6H2,(H2,11,12,14)(H2,16,17,18)
描述信息
C254 - Anti-Infective Agent > C281 - Antiviral Agent
同义名列表
6 个代谢物同义名
((1-((2-Amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid di(pivaloyloxymethyl) ester; ((1-((2-Amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl; ({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropoxy}methyl)phosphonic acid; {1-[(2-aminopurin-9-yl)methyl]cyclopropoxy}methylphosphonic acid; PMCDG Dipivoxyl; Besifovir
数据库引用编号
6 个数据库交叉引用编号
- PubChem: 5270766
- HMDB: HMDB0249090
- ChEMBL: CHEMBL329091
- Wikipedia: Besifovir
- chemspider: 4435660
- CAS: 441785-25-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。
文献列表
- Jun Gi Hwang, Yu Kyong Kim, Young-Sim Choi, Soon Kil Kwon, Joung-Ho Han, Min Kyu Park. Influence of Renal Function on the Single-Dose Pharmacokinetics of Besifovir, a Novel Antiviral Agent for theTreatment of Hepatitis B Virus Infection.
Journal of clinical pharmacology.
2022 01; 62(1):46-54. doi:
10.1002/jcph.1945
. [PMID: 34327707] - Lung-Yi Mak, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen. Pharmacokinetic evaluation of besifovir for the treatment of HBV infection.
Expert opinion on drug metabolism & toxicology.
2018 Jan; 14(1):101-106. doi:
10.1080/17425255.2018.1417983
. [PMID: 29237296] - Ching-Lung Lai, Sang Hoon Ahn, Kwan Sik Lee, Soon Ho Um, Mong Cho, Seung Kew Yoon, Jin-Woo Lee, Neung Hwa Park, Young-Oh Kweon, Joo Hyun Sohn, Jiyoon Lee, Jeong-Ae Kim, Kwang-Hyub Han, Man-Fung Yuen. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B.
Gut.
2014 Jun; 63(6):996-1004. doi:
10.1136/gutjnl-2013-305138
. [PMID: 23979965] - Jin Ah Jung, Suk Ran Kim, Tae-Eun Kim, Jung-Ryul Kim, Soo-Youn Lee, Wooseong Huh, Jae-Wook Ko. Pharmacokinetic comparison of the maleate and free base formulations of LB80380, a novel nucleotide analog, in healthy male volunteers.
International journal of clinical pharmacology and therapeutics.
2012 Sep; 50(9):657-64. doi:
10.5414/cp201716
. [PMID: 22981147] - Man-Fung Yuen, Sung-Hack Lee, Hyang-Mi Kang, Chung Ryeol Kim, John Kim, Vincent Ngai, Ching-Lung Lai. Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice.
Antimicrobial agents and chemotherapy.
2009 May; 53(5):1779-85. doi:
10.1128/aac.01290-08
. [PMID: 19223649]